Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: Predictors for successful treatment and survival

Shunji Nagai, Richard Mangus, Chandrashekhar A. Kubal, Burcin Ekser, Jonathan A. Fridell, Kendell R. Klingler, Mary Maluccio, A. Joseph Tector

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There are no established prognostic factors or standardized therapies for hepatocellular carcinoma (HCC) recurrence in liver transplantation (LT). The aim of this study was to investigate impact of underlying patient condition on treatment and outcomes of recurrence of HCC after LT. The medical records of 268 LT patients with HCC were evaluated. Potential prognostic factors for survival after recurrence were evaluated, including recurrent tumor characteristics, medical/radiological/surgical therapies for recurrence, and an inflammatory marker (neutrophil/lymphocyte ratio). Laboratory tests at recurrence, including albumin, absolute lymphocyte count (ALC), prognostic nutritional index (PNI: ALC(/μL) × 0.005 + Albumin(g/dL) × 10), were evaluated as surrogate markers for underlying patient conditions. A total of 51 (19%) patients developed HCC recurrence. The use of sirolimus and sorafenib significantly improved outcome (p = 0.007 and 0.04), and better nutritional status (PNI ≥ 40) enhanced their efficacy. On multivariate analysis, low ALC (<500/μL) and albumin (<2.8 g/L) remained independent prognostic factors (p = 0.03 and 0.02; hazard ratio = 3.61 [Ref. >1000/μL] and 4.97 [Ref. >3.5 g/dL], respectively). Low PNI (<40) showed significantly lower survival rate after adjusting the risk (p = 0.006, hazard ratio = 3.29). Underlying patient conditions and nutritional status, represented by ALC and albumin, are important to successful cancer treatment and strong prognostic markers for survival after HCC recurrence.

Original languageEnglish (US)
Pages (from-to)1156-1163
Number of pages8
JournalClinical Transplantation
Volume29
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Recurrence
Lymphocyte Count
Survival
Albumins
Nutritional Status
Therapeutics
Nutrition Assessment
Sirolimus
Medical Records
Neoplasms
Neutrophils
Multivariate Analysis
Survival Rate
Biomarkers
Lymphocytes

Keywords

  • Chemotherapy
  • Hepatocellular carcinoma
  • Liver transplantation
  • Nutrition
  • Prognostic nutritional index
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Transplantation

Cite this

Prognosis after recurrence of hepatocellular carcinoma in liver transplantation : Predictors for successful treatment and survival. / Nagai, Shunji; Mangus, Richard; Kubal, Chandrashekhar A.; Ekser, Burcin; Fridell, Jonathan A.; Klingler, Kendell R.; Maluccio, Mary; Tector, A. Joseph.

In: Clinical Transplantation, Vol. 29, No. 12, 01.12.2015, p. 1156-1163.

Research output: Contribution to journalArticle

Nagai, Shunji ; Mangus, Richard ; Kubal, Chandrashekhar A. ; Ekser, Burcin ; Fridell, Jonathan A. ; Klingler, Kendell R. ; Maluccio, Mary ; Tector, A. Joseph. / Prognosis after recurrence of hepatocellular carcinoma in liver transplantation : Predictors for successful treatment and survival. In: Clinical Transplantation. 2015 ; Vol. 29, No. 12. pp. 1156-1163.
@article{719a69bd34a7451f9f8ad67e1e730518,
title = "Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: Predictors for successful treatment and survival",
abstract = "There are no established prognostic factors or standardized therapies for hepatocellular carcinoma (HCC) recurrence in liver transplantation (LT). The aim of this study was to investigate impact of underlying patient condition on treatment and outcomes of recurrence of HCC after LT. The medical records of 268 LT patients with HCC were evaluated. Potential prognostic factors for survival after recurrence were evaluated, including recurrent tumor characteristics, medical/radiological/surgical therapies for recurrence, and an inflammatory marker (neutrophil/lymphocyte ratio). Laboratory tests at recurrence, including albumin, absolute lymphocyte count (ALC), prognostic nutritional index (PNI: ALC(/μL) × 0.005 + Albumin(g/dL) × 10), were evaluated as surrogate markers for underlying patient conditions. A total of 51 (19{\%}) patients developed HCC recurrence. The use of sirolimus and sorafenib significantly improved outcome (p = 0.007 and 0.04), and better nutritional status (PNI ≥ 40) enhanced their efficacy. On multivariate analysis, low ALC (<500/μL) and albumin (<2.8 g/L) remained independent prognostic factors (p = 0.03 and 0.02; hazard ratio = 3.61 [Ref. >1000/μL] and 4.97 [Ref. >3.5 g/dL], respectively). Low PNI (<40) showed significantly lower survival rate after adjusting the risk (p = 0.006, hazard ratio = 3.29). Underlying patient conditions and nutritional status, represented by ALC and albumin, are important to successful cancer treatment and strong prognostic markers for survival after HCC recurrence.",
keywords = "Chemotherapy, Hepatocellular carcinoma, Liver transplantation, Nutrition, Prognostic nutritional index, Recurrence, Survival",
author = "Shunji Nagai and Richard Mangus and Kubal, {Chandrashekhar A.} and Burcin Ekser and Fridell, {Jonathan A.} and Klingler, {Kendell R.} and Mary Maluccio and Tector, {A. Joseph}",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/ctr.12644",
language = "English (US)",
volume = "29",
pages = "1156--1163",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Prognosis after recurrence of hepatocellular carcinoma in liver transplantation

T2 - Predictors for successful treatment and survival

AU - Nagai, Shunji

AU - Mangus, Richard

AU - Kubal, Chandrashekhar A.

AU - Ekser, Burcin

AU - Fridell, Jonathan A.

AU - Klingler, Kendell R.

AU - Maluccio, Mary

AU - Tector, A. Joseph

PY - 2015/12/1

Y1 - 2015/12/1

N2 - There are no established prognostic factors or standardized therapies for hepatocellular carcinoma (HCC) recurrence in liver transplantation (LT). The aim of this study was to investigate impact of underlying patient condition on treatment and outcomes of recurrence of HCC after LT. The medical records of 268 LT patients with HCC were evaluated. Potential prognostic factors for survival after recurrence were evaluated, including recurrent tumor characteristics, medical/radiological/surgical therapies for recurrence, and an inflammatory marker (neutrophil/lymphocyte ratio). Laboratory tests at recurrence, including albumin, absolute lymphocyte count (ALC), prognostic nutritional index (PNI: ALC(/μL) × 0.005 + Albumin(g/dL) × 10), were evaluated as surrogate markers for underlying patient conditions. A total of 51 (19%) patients developed HCC recurrence. The use of sirolimus and sorafenib significantly improved outcome (p = 0.007 and 0.04), and better nutritional status (PNI ≥ 40) enhanced their efficacy. On multivariate analysis, low ALC (<500/μL) and albumin (<2.8 g/L) remained independent prognostic factors (p = 0.03 and 0.02; hazard ratio = 3.61 [Ref. >1000/μL] and 4.97 [Ref. >3.5 g/dL], respectively). Low PNI (<40) showed significantly lower survival rate after adjusting the risk (p = 0.006, hazard ratio = 3.29). Underlying patient conditions and nutritional status, represented by ALC and albumin, are important to successful cancer treatment and strong prognostic markers for survival after HCC recurrence.

AB - There are no established prognostic factors or standardized therapies for hepatocellular carcinoma (HCC) recurrence in liver transplantation (LT). The aim of this study was to investigate impact of underlying patient condition on treatment and outcomes of recurrence of HCC after LT. The medical records of 268 LT patients with HCC were evaluated. Potential prognostic factors for survival after recurrence were evaluated, including recurrent tumor characteristics, medical/radiological/surgical therapies for recurrence, and an inflammatory marker (neutrophil/lymphocyte ratio). Laboratory tests at recurrence, including albumin, absolute lymphocyte count (ALC), prognostic nutritional index (PNI: ALC(/μL) × 0.005 + Albumin(g/dL) × 10), were evaluated as surrogate markers for underlying patient conditions. A total of 51 (19%) patients developed HCC recurrence. The use of sirolimus and sorafenib significantly improved outcome (p = 0.007 and 0.04), and better nutritional status (PNI ≥ 40) enhanced their efficacy. On multivariate analysis, low ALC (<500/μL) and albumin (<2.8 g/L) remained independent prognostic factors (p = 0.03 and 0.02; hazard ratio = 3.61 [Ref. >1000/μL] and 4.97 [Ref. >3.5 g/dL], respectively). Low PNI (<40) showed significantly lower survival rate after adjusting the risk (p = 0.006, hazard ratio = 3.29). Underlying patient conditions and nutritional status, represented by ALC and albumin, are important to successful cancer treatment and strong prognostic markers for survival after HCC recurrence.

KW - Chemotherapy

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Nutrition

KW - Prognostic nutritional index

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84983108461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983108461&partnerID=8YFLogxK

U2 - 10.1111/ctr.12644

DO - 10.1111/ctr.12644

M3 - Article

C2 - 26458066

AN - SCOPUS:84983108461

VL - 29

SP - 1156

EP - 1163

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 12

ER -